房颤导管消融成功后抗凝
Anticoagulation after Successful Catheter Ablation of Atrial Fibrillation
DOI: 10.12677/ACM.2020.109284, PDF,   
作者: 王丽娟：武汉科技大学医学院，湖北 武汉；汪 敏*, 双东思：武汉亚洲心脏病医院，湖北 武汉
关键词: 心房颤动；导管消融；口服抗凝停止；卒中；Atrial Fibrillation； Catheter Ablation； Anticoagulant； Stroke
摘要: 房颤患者有发生脑血管栓塞事件(cerebrovascular embolic events, CVEs)的风险，包括卒中和短暂性脑缺血发作。口服抗凝药物治疗(oral anticoagulation therapy, OAT)可以有效地预防CVE，而导管消融(catheter ablation, CA)治疗房颤已成为部分患者最有效的节律控制策略。尽管有回顾性研究认为通过CA消除房颤或减轻房颤负担可能会显著降低卒中风险，然而在导管消融成功后是否可以安全地停止OAT仍然是一个有争议的话题。
Abstract: Patients with atrial fibrillation are at risk for thromboembolic events (cerebrovascularembolicevents, CVEs), including stroke and transient ischemic attacks. Anticoagulant therapy (oralanticoagulation therapy, OAT) can effectively prevent CVE, catheter ablation (catheterablation, CA) in the treatment of atrial fibrillation has become the most effective rhythm control strategy for some patients. Although retrospective studies have suggested that eliminating atrial fibrillation or reducing the burden of atrial fibrillation through CA may significantly reduce stroke risk, whether OAT can be stopped safely after successful catheter ablation is still a controversial topic.
文章引用：王丽娟, 汪敏, 双东思. 房颤导管消融成功后抗凝[J]. 临床医学进展, 2020, 10(9): 1892-1898. https://doi.org/10.12677/ACM.2020.109284

参考文献

[1] Rahman, F., Kwan, G.F. and Benjamin, E.J. (2014) Global Epidemiology of Atrial Fibrillation. Nature Reviews Cardiology, 11, 639-654. [Google Scholar] [CrossRef] [PubMed]
[2] Guo, Y., Tian, Y., Wang, H., et al. (2015) Prevalence, Incidence, and Lifetime Risk of Atrial Fibrillation in China: New Insights into the Global Burden of Atrial Fibrillation. Chest, 147, 109-119. [Google Scholar] [CrossRef] [PubMed]
[3] Wang, X., Fu, Q., Song, F., et al. (2018) Prevalence of Atrial Fibrillation in Different Socioeconomic Regions of China and Its Association with Stroke: Results from a National Stroke Screening Survey. International Journal of Cardiology, 271, 92-97. [Google Scholar] [CrossRef] [PubMed]
[4] Jagadish, P.S., Kirolos, I., Khare, S., et al. (2019) Post-Operative Atrial Fibrillation: Should We Anticoagulate? Annals of Translational Medicine, 7, 407. [Google Scholar] [CrossRef] [PubMed]
[5] Kirchhof, P., Benussi, S., Kotecha, D., et al. (2017) 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with EACTS. Revista Española de Cardiología, 70, 50. [Google Scholar] [CrossRef] [PubMed]
[6] Bjorck, S., Palaszewski, B., Friberg, L., et al. (2013) Atrial Fibrillation, Stroke Risk, and Warfarin Therapy Revisited: A Population-Based Study. Stroke, 44, 3103-3108. [Google Scholar] [CrossRef] 
[7] Calkins, H., Kuck, K.H., Cappato, R., et al. (2012) 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-Up, Definitions, Endpoints, and Research Trial Design. Journal of Interventional Cardiac Electrophysiology, 33, 171-257. [Google Scholar] [CrossRef] [PubMed]
[8] Yaghi, S., Boehme, A.K., Hazan, R., et al. (2016) Atrial Cardiopathy and Cryptogenic Stroke: A Cross-Sectional Pilot Study. Journal of Stroke and Cerebrovascular Diseases, 25, 110-114. [Google Scholar] [CrossRef] [PubMed]
[9] Brambatti, M., Connolly, S.J., Gold, M.R., et al. (2014) Temporal Relationship between Subclinical Atrial Fibrillation and Embolic Events. Circulation, 129, 2094-2099. [Google Scholar] [CrossRef] 
[10] Mitchell, L.B., Southern, D.A., Galbraith, D., et al. (2014) Prediction of Stroke or TIA in Patients without Atrial Fibrillation Using CHADS2 and CHA2DS2-VASc Scores. Heart, 100, 1524-1530. [Google Scholar] [CrossRef] [PubMed]
[11] Overvad, T.F., Nielsen, P.B., Larsen, T.B., et al. (2016) Left Atrial Size and Risk of Stroke in Patients in Sinus Rhythm. A Systematic Review. Thrombosis and Haemostasis, 116, 206-219. [Google Scholar] [CrossRef] 
[12] T andon, K., Tirschwell, D., Longstreth, W.T., et al. (2019) Embolic Stroke of Undetermined Source Correlates to Atrial Fibrosis without Atrial Fibrillation. Neurology, 93, e381-e387. [Google Scholar] [CrossRef] 
[13] Calkins, H., Hindricks, G., Cappato, R., et al. (2017) 2017 HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation. Heart Rhythm: The Official Journal of the Heart Rhythm Society, 14, e275-e444.
[14] Friberg, L., Tabrizi, F. and Englund, A. (2016) Catheter Ablation for Atrial Fibrillation Is Associated with Lower Incidence of Stroke and Death: Data from Swedish Health Registries. European Heart Journal, 37, 2478-2487. [Google Scholar] [CrossRef] [PubMed]
[15] Saliba, W., Schliamser, J.E., Lavi, I., Barnett-Griness, O., Gronich, N. and Rennert, G. (2017) Catheter Ablation of Atrial Fibrillation Is Associated with Reduced Risk of Stroke and Mortality: A Propensity Score-Matched Analysis. Heart Rhythm, 14, 635-642. [Google Scholar] [CrossRef] [PubMed]
[16] Packer, D.L., Mark, D.B., Robb, R.A., Monahan, K.H., Bahnson, T.D., Poole, J.E., et al. (2019) Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest among Patients with Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA, 321, 1261-1274. [Google Scholar] [CrossRef] [PubMed]
[17] Själander, S., Holmqvist, F., Smith, J., et al. (2017) Assessment of Use vs Discontinuation of Oral Anticoagulation after Pulmonary Vein Isolationin Patients with Atrial Fibrillation. JAMA Cardiology, 2, 146-152. [Google Scholar] [CrossRef] [PubMed]
[18] Marchlinski, F.E. and Santangeli, P. (2017) When Does High Risk for Stroke Become Low Risk after Atrial Fibrillation Ablation? JAMA Cardiology, 2, 152-154. [Google Scholar] [CrossRef] [PubMed]
[19] Themistoclakis, S., Corrado, A., Marchlinski, F.E., Jais, P., Zado, E., Rossillo, A., et al. (2010) The Risk of Thromboembolism and Need for Oral Anticoagulation after Successful Atrial Fibrillation Ablation. Journal of the American College of Cardiology, 55, 735-743. [Google Scholar] [CrossRef] [PubMed]
[20] Liang, J.J., Elafros, M.A., Mullen, M.T., Muser, D., Hayashi, T., Enriquez, A., et al. (2018) Anticoagulation Use and Clinical Outcomes after Catheter Ablation in Patients with Persistent and Longstanding Persistent Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 29, 823-832. [Google Scholar] [CrossRef] [PubMed]
[21] Romero, J., Cerrud-Rodriguez, R.C., Diaz, J.C., et al. (2019) Oral Anticoagulation after Catheter Ablation of Atrial Fibrillation and the Associated Risk of Thromboembolic Events and Intracranial Hemorrhage: A Systematic Review and Meta-Analysis. Journal of Cardiovascular Electrophysiology, 30, 1250-1257. [Google Scholar] [CrossRef] [PubMed]
[22] Yu, R., Xi, H., Lu, J., et al. (2020) Real-World Investigation on Discontinuation of Oral Anticoagulation after Paroxysmal Atrial Fibrillation Catheter Ablation in China. Annals of Palliative Medicine, 9, 940-946. [Google Scholar] [CrossRef] [PubMed]
[23] Birnie, D.H., Smith, E.E. and Verma, A. (2019) To Continue or Stop Oral Anti-Coagulation in Higher-Risk Patients after a “Successful” AF Ablation; That Is the Question. Journal of Cardiovascular Electrophysiology, 30, 1258-1260. [Google Scholar] [CrossRef] [PubMed]
[24] Freeman, J.V., Shrader, P., Pieper, K.S., et al. (2019) Outcomes and Anticoagulation Use after Catheter Ablation for Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 12, e007612. [Google Scholar] [CrossRef] 
[25] Yang, W.Y., Du, X., Jiang, C., et al. (2020) The Safety of Discontinuation of Oral Anticoagulation Therapy after Apparently Successful Atrial Fibrillation Ablation: A Report from the Chinese Atrial Fibrillation Registry Study. Europace, 22, 90-99. [Google Scholar] [CrossRef] [PubMed]
[26] Liang, B., Zhao, Y.X. and Gu, N. (2020) Discontinuation of Oral Anticoagulation Therapy after Apparently Successful Atrial Fibrillation Ablation. Europace, 22, 1143-1144. [Google Scholar] [CrossRef] [PubMed]
[27] Terricabras, M. and Verma, A. (2020) Stopping Oral Anticoagulation after Successful Ablation for Atrial Fibrillation: Reality or Fiction? Europace, 22, 1-2. [Google Scholar] [CrossRef] [PubMed]
[28] Liang, J.J., Dixit, S. and Santangeli, P. (2016) Mechanisms and Clinical Significance of Early Recurrences of Atrial Arrhythmias after Catheter Ablation for Atrial Fibrillation. World Journal of Cardiology, 8, 638-646. [Google Scholar] [CrossRef] [PubMed]
[29] Andrade, J.G., Khairy, P., Verma, A., et al. (2012) Early Recurrence of Atrial Tachyarrhythmias Following Radiofrequency Catheter Ablation of Atrial Fibrillation. Pacing and Clinical Electrophysiology, 35, 106-116. [Google Scholar] [CrossRef] [PubMed]
[30] Takigawa, M., Takahashi, A., Kuwahara, T., et al. (2014) Long-Term Follow-Up after Catheter Ablation of Paroxysmal Atrial Fibrillation: The Incidence of Recurrence and Progression of Atrial Fibrillation. Circulation Arrhythmia and Electrophysiology, 7, 267-273. [Google Scholar] [CrossRef] 
[31] McManus, D.D., Chong, J.W., Soni, A., Saczynski, J.S., Esa, N., Napolitano, C., et al. (2016) PULSE-SMART: Pulse-Based Arrhythmia Discrimination Using a Novel Smartphone Application. Journal of Cardiovascular Electrophysiology, 27, 51-57. [Google Scholar] [CrossRef] [PubMed]
[32] Sepehri Shamloo, A., Bollmann, A., Dagres, N., Arya, A. and Hindricks, G. (2020) Smart Watch Devices for Atrial Fibrillation Screening: It Has to Start Somewhere. Journal of the American College of Cardiology, 75, 1364-1365. [Google Scholar] [CrossRef] [PubMed]
[33] Seshadri, D.R., Bittel, B., Browsky, D., Houghtaling, P., Drummond, C.K., Desai, M.Y., et al. (2020) Accuracy of Apple Watch for Detection of Atrial Fibrillation. Circulation, 141, 702-703. [Google Scholar] [CrossRef] 
[34] Koshy, A.N., Sajeev, J.K., Nerlekar, N., Brown, A.J., Rajakariar, K., Zureik, M., et al. (2018) Smart Watches for Heart Rate Assessment in Atrial Arrhythmias. International Journal of Cardiology, 266, 124-127. [Google Scholar] [CrossRef] [PubMed]
[35] Kaplan, R.M., Koehler, J., Ziegler, P.D., Sarkar, S., Zweibel, S. and Passman, R.S. (2019) Stroke Risk as a Function of Atrial Fibrillation Duration and CHA2DS2-VASc Score. Circulation, 140, 1639-1646. [Google Scholar] [CrossRef] 
[36] Verma, A., Ha, A.C.T., Kirchhof, P., et al. (2018) The Optimal Anticoagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) Trial. American Heart Journal, 197, 124-132. [Google Scholar] [CrossRef] [PubMed]

为你推荐